Cargando…
Mesenchymal Stem/Stromal Cells: MESENCURE: A PROFESSIONALIZED CELL THERAPY FOR ARDS REDUCED THE MORTALITY OF SEVERE COVID-19 PATIENTS BY 68% ACCORDING TO A RECENTLY CONCLUDED MULTI-CENTER, CONTROLLED PHASE II STUDY
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
International Society for Cell & Gene Therapy. Published by Elsevier Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035762/ http://dx.doi.org/10.1016/S1465-3249(22)00134-7 |
| _version_ | 1784693369037914112 |
|---|---|
| author | Bronshtein, T. David, D. Ben Novak, A. Kivity, V. Hayek, T. Rozen, N. Meretzki, S. Hamoud, S. |
| author_facet | Bronshtein, T. David, D. Ben Novak, A. Kivity, V. Hayek, T. Rozen, N. Meretzki, S. Hamoud, S. |
| author_sort | Bronshtein, T. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9035762 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | International Society for Cell & Gene Therapy. Published by Elsevier Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-90357622022-04-25 Mesenchymal Stem/Stromal Cells: MESENCURE: A PROFESSIONALIZED CELL THERAPY FOR ARDS REDUCED THE MORTALITY OF SEVERE COVID-19 PATIENTS BY 68% ACCORDING TO A RECENTLY CONCLUDED MULTI-CENTER, CONTROLLED PHASE II STUDY Bronshtein, T. David, D. Ben Novak, A. Kivity, V. Hayek, T. Rozen, N. Meretzki, S. Hamoud, S. Cytotherapy Oral Abstracts International Society for Cell & Gene Therapy. Published by Elsevier Inc. 2022-05 2022-04-25 /pmc/articles/PMC9035762/ http://dx.doi.org/10.1016/S1465-3249(22)00134-7 Text en Copyright © 2022 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Oral Abstracts Bronshtein, T. David, D. Ben Novak, A. Kivity, V. Hayek, T. Rozen, N. Meretzki, S. Hamoud, S. Mesenchymal Stem/Stromal Cells: MESENCURE: A PROFESSIONALIZED CELL THERAPY FOR ARDS REDUCED THE MORTALITY OF SEVERE COVID-19 PATIENTS BY 68% ACCORDING TO A RECENTLY CONCLUDED MULTI-CENTER, CONTROLLED PHASE II STUDY |
| title | Mesenchymal Stem/Stromal Cells: MESENCURE: A PROFESSIONALIZED CELL THERAPY FOR ARDS REDUCED THE MORTALITY OF SEVERE COVID-19 PATIENTS BY 68% ACCORDING TO A RECENTLY CONCLUDED MULTI-CENTER, CONTROLLED PHASE II STUDY |
| title_full | Mesenchymal Stem/Stromal Cells: MESENCURE: A PROFESSIONALIZED CELL THERAPY FOR ARDS REDUCED THE MORTALITY OF SEVERE COVID-19 PATIENTS BY 68% ACCORDING TO A RECENTLY CONCLUDED MULTI-CENTER, CONTROLLED PHASE II STUDY |
| title_fullStr | Mesenchymal Stem/Stromal Cells: MESENCURE: A PROFESSIONALIZED CELL THERAPY FOR ARDS REDUCED THE MORTALITY OF SEVERE COVID-19 PATIENTS BY 68% ACCORDING TO A RECENTLY CONCLUDED MULTI-CENTER, CONTROLLED PHASE II STUDY |
| title_full_unstemmed | Mesenchymal Stem/Stromal Cells: MESENCURE: A PROFESSIONALIZED CELL THERAPY FOR ARDS REDUCED THE MORTALITY OF SEVERE COVID-19 PATIENTS BY 68% ACCORDING TO A RECENTLY CONCLUDED MULTI-CENTER, CONTROLLED PHASE II STUDY |
| title_short | Mesenchymal Stem/Stromal Cells: MESENCURE: A PROFESSIONALIZED CELL THERAPY FOR ARDS REDUCED THE MORTALITY OF SEVERE COVID-19 PATIENTS BY 68% ACCORDING TO A RECENTLY CONCLUDED MULTI-CENTER, CONTROLLED PHASE II STUDY |
| title_sort | mesenchymal stem/stromal cells: mesencure: a professionalized cell therapy for ards reduced the mortality of severe covid-19 patients by 68% according to a recently concluded multi-center, controlled phase ii study |
| topic | Oral Abstracts |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035762/ http://dx.doi.org/10.1016/S1465-3249(22)00134-7 |
| work_keys_str_mv | AT bronshteint mesenchymalstemstromalcellsmesencureaprofessionalizedcelltherapyforardsreducedthemortalityofseverecovid19patientsby68accordingtoarecentlyconcludedmulticentercontrolledphaseiistudy AT daviddben mesenchymalstemstromalcellsmesencureaprofessionalizedcelltherapyforardsreducedthemortalityofseverecovid19patientsby68accordingtoarecentlyconcludedmulticentercontrolledphaseiistudy AT novaka mesenchymalstemstromalcellsmesencureaprofessionalizedcelltherapyforardsreducedthemortalityofseverecovid19patientsby68accordingtoarecentlyconcludedmulticentercontrolledphaseiistudy AT kivityv mesenchymalstemstromalcellsmesencureaprofessionalizedcelltherapyforardsreducedthemortalityofseverecovid19patientsby68accordingtoarecentlyconcludedmulticentercontrolledphaseiistudy AT hayekt mesenchymalstemstromalcellsmesencureaprofessionalizedcelltherapyforardsreducedthemortalityofseverecovid19patientsby68accordingtoarecentlyconcludedmulticentercontrolledphaseiistudy AT rozenn mesenchymalstemstromalcellsmesencureaprofessionalizedcelltherapyforardsreducedthemortalityofseverecovid19patientsby68accordingtoarecentlyconcludedmulticentercontrolledphaseiistudy AT meretzkis mesenchymalstemstromalcellsmesencureaprofessionalizedcelltherapyforardsreducedthemortalityofseverecovid19patientsby68accordingtoarecentlyconcludedmulticentercontrolledphaseiistudy AT hamouds mesenchymalstemstromalcellsmesencureaprofessionalizedcelltherapyforardsreducedthemortalityofseverecovid19patientsby68accordingtoarecentlyconcludedmulticentercontrolledphaseiistudy |